Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

被引:14
|
作者
Chanthavanich, Pornthep [1 ]
Limkittikul, Kriengsak [1 ]
Sirivichayakul, Chukiat [1 ]
Chokejindachai, Watcharee [1 ]
Hattasingh, Weerawan [1 ]
Pengsaa, Krisana [1 ]
Surangsrirat, Surachai [2 ]
Srisuwannaporn, Termsang [2 ]
Kaewma, Benjawan [2 ]
Yoksan, Sutee [3 ]
Jun, Gao [4 ]
Zhumu, Bai [4 ]
机构
[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, 420-6 Rajvithi Rd, Bangkok 10400, Thailand
[2] Nopparat Rajathanee Hosp, Minist Publ Hlth, Bangkok, Thailand
[3] Mahidol Univ, Inst Mol Biosci, Ctr Vaccine Dev, Japanese Encephalitis Dengue Virol Lab, Bangkok, Thailand
[4] Liaoning Cheng Da Biotechnol Co Ltd, Shenyang, Liaoning, Peoples R China
关键词
children; chromatographical purify; immunogenicity; Inactivated Vero cell-derived JE vaccine; pediatrics; safety; vaccinology; TRAVELERS;
D O I
10.1080/21645515.2017.1414763
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7-28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions-fever (17.6%), vomiting (8%), and poor appetite (5.3%)-were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.
引用
收藏
页码:900 / 905
页数:6
相关论文
共 50 条
  • [1] Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
    Hattasingh, Weerawan
    Chanthavanich, Pornthep
    Sirivichayakul, Chukiat
    Arunsodsai, Watcharee
    Surangsrirat, Surachai
    Srisuwannaporn, Termsang
    Kaewma, Benjawan
    Yoksan, Sutee
    Limkittikul, Kriengsak
    Yang, Junwei
    Mao, Yu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [2] Development of Vero cell-derived inactivated Japanese encephalitis vaccine
    Sugawara, K
    Nishiyama, K
    Ishikawa, Y
    Abe, M
    Sonoda, K
    Komatsu, K
    Horikawa, Y
    Takeda, K
    Honda, T
    Kuzuhara, S
    Kino, Y
    Mizokami, H
    Mizuno, K
    Oka, T
    Honda, K
    BIOLOGICALS, 2002, 30 (04) : 303 - 314
  • [3] Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults
    Takeshita, Nozomi
    Lim, Chang-Kweng
    Mizuno, Yasutaka
    Shimbo, Takuro
    Kotaki, Akira
    Ujiie, Mugen
    Hayakawa, Kayoko
    Kato, Yasuyuki
    Kanagawa, Shuzo
    Kaku, Mitsuo
    Takasaki, Tomohiko
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2014, 20 (3-4) : 238 - 242
  • [4] Vero cell derived novel inactivated Japanese encephalitis vaccine JENVACR
    Ramasamy, V.
    Duvvuri, P. K.
    Kaushik, Y.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 45 : 418 - 418
  • [5] Immunogenicity and safety study of Indirab: A Vero cell based chromatographically purified human rabies vaccine
    Sampath, Gadey
    Madhusudana, Shampur Narayan
    Sudarshan, Mysore Kalappa
    Ashwathnarayana, Doddabele Hanumanthaiah
    Mahendra, Bangalore Jayakrishna
    Ullas, Thankappan P.
    Mohan, Krishna
    Madhusudhan, Santhosh Kumar
    Ravish, Haradanahalli Shankariah
    VACCINE, 2010, 28 (24) : 4086 - 4090
  • [6] Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO®
    Schuller, Elisabeth
    Klingler, Anton
    Dubischar-Kastner, Katrin
    Dewasthaly, Shailesh
    Mueller, Zsuzsanna
    VACCINE, 2011, 29 (47) : 8669 - 8676
  • [7] A purified inactivated Japanese encephalitis virus vaccine made in vero cells
    Srivastava, AK
    Putnak, JR
    Lee, SH
    Hong, SP
    Moon, SB
    Barvir, DA
    Zhao, BT
    Olson, RA
    Kim, SO
    Yoo, WD
    Towle, AC
    Vaughn, DW
    Innis, BL
    Eckels, KH
    VACCINE, 2001, 19 (31) : 4557 - 4565
  • [8] Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine
    Kuzuhara, S
    Nakamura, H
    Hayashida, K
    Obata, J
    Abe, M
    Sonoda, K
    Nishiyama, K
    Sugawara, K
    Takeda, K
    Honda, T
    Matsui, H
    Shigaki, T
    Kino, Y
    Mizokami, H
    Tanaka, M
    Mizuno, K
    Ueda, K
    VACCINE, 2003, 21 (31) : 4519 - 4526
  • [9] Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine
    Kino, Y
    Kuzuhara, S
    Nakamura, H
    Hayashida, K
    Obata, J
    Abe, M
    Sonoda, K
    Nishiyama, K
    Sugawara, K
    Takeda, K
    Honda, T
    Matsui, H
    Shigaki, T
    Mizokami, HR
    Tanaka, M
    Mizuno, K
    Ueda, K
    JOURNAL OF CLINICAL VIROLOGY, 2003, 28 : S70 - S70
  • [10] One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series
    Cramer, Jakob P.
    Jelinek, Tomas
    Paulke-Korinek, Maria
    Reisinger, Emil C.
    Dieckmann, Sebastian
    Alberer, Martin
    Buhler, Silja
    Bosse, Dietrich
    Meyer, Seetha
    Fragapane, Elena
    Costantini, Marco
    Pellegrini, Michele
    Lattanzi, Maria
    Dovali, Claudia
    JOURNAL OF TRAVEL MEDICINE, 2016, 23 (03)